Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma.
Clin Cancer Res
; 21(12): 2677-83, 2015 Jun 15.
Article
in En
| MEDLINE
| ID: mdl-25792568
ABSTRACT
Smoothened inhibitors represent the first class of targeted drugs approved for use in advanced and metastatic basal cell carcinoma. For many patients with limited treatment options, this drug class has led to significant clinical improvements, but is not without side effects. In this review, we outline the basic mechanism of smoothened inhibitors and the most commonly observed cutaneous and extracutaneous side effects. We also highlight possible mechanisms for these adverse events and current management strategies.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Basal Cell
/
Receptors, G-Protein-Coupled
/
Drug-Related Side Effects and Adverse Reactions
/
Antineoplastic Agents
Type of study:
Diagnostic_studies
/
Etiology_studies
Limits:
Humans
Language:
En
Journal:
Clin Cancer Res
Year:
2015
Document type:
Article